Galectin Therapeutics is a clinical stage biopharmaceutical company that is focused on research and development of therapies for fibrotic disease and cancer. The company’s lead product candidates are GR-MD-02, a complex polysaccharide polymer for the treatment of liver fibrosis and fatty liver disease; and GM-CT-01, a linear polysaccharide polymer comprising mannose and galactose that is in a phase 1/2 clinical trials in Belgium as a combination with a tumor vaccine in patients with advanced melanoma, a skin cancer.  For more information, visit the company’s website at www.galectintherapeutics.com